Brief: Burning Rock Biotech Reiterates 2023 FY Revenue Guidance Of About 20% Growth Over 2022
30/05/2023 07:17
May 30 (Reuters) - Burning Rock Biotech Ltd BNR.O :
* BURNING ROCK BIOTECH LTD Q1 REVENUE ROSE 5.2 PERCENT TO
142.5
MILLION RMB
* BURNING ROCK BIOTECH LTD Q1 GROSS PROFIT ROSE 12.8 PERCENT
TO
98.8 MILLION RMB
* BURNING ROCK BIOTECH LTD - REITERATE 2023 FULL-YEAR
REVENUE
GUIDANCE OF ABOUT 20% GROWTH OVER 2022
Source text for Eikon: urn:newsml:reuters.com:*:nRSd9883Aa
Further company coverage: BNR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Burning Rock Biotech
See all newsBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
China's Burning Rock Biotech Q4 net loss narrows as costs fall
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer